biologic

mnexspike

COVID-19 Vaccine, mRNA

Loss of exclusivityMay 2037projected — 12-year biologic exclusivity estimate
CompanyModernaTX, Inc.

Drug detail

Brand namemnexspike
Active ingredientCOVID-19 Vaccine, mRNA
Strength10UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalMay 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

mnexspike patent cliff — loss of exclusivity May 2037 | CliffBio